29.03.2010 • News

Glaxo Seeks Out Japanese Partnerships

GlaxoSmithKline is looking to join up with small and medium-sized companies in Japan to help it develop and distribute new medicines, the Financial Times reported in its Monday edition. Glaxo's Asia-Pacific head Marc Dunoyer said the British drugs firm was looking to work with and invest in firms but would not take a controlling stake.

"The medium-sized segment of Japan is where we're going to focus our attention," Dunoyer was cited as saying in the FT. "It's about reassuring them that we're not going to take them out, but that we have some complementary areas," Dunoyer said.

Glaxo is eyeing new opportunities in Japan, where a raft of medicines that are already well established in home markets are winning approval and being launched. Emerging markets, with nine-month sales of £2.1 billion and year-on-year growth of 19%, currently make up 13% of Glaxo group sales. Japan accounts for some 4%.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.